52 research outputs found
Patent No. US 9,090,589 B2: Specific NNOS Inhibitors for the Therapy and Prevention of Human Melanoma
Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies
Tower 1978
1978 yearbook of Westbrook College in Portland, Maine.https://dune.une.edu/wchc_yearbooks/1007/thumbnail.jp
Impact of Substrate Protonation and Tautomerization States on Interactions with the Active Site of Arginase I
Human arginase is a binuclear manganese metalloenzyme
that participates
in the urea cycle. Arginase catalyzes the hydrolysis of l-arginine into l-ornithine and urea and is linked to several
disorders such as asthma and cancer. Currently, the protonation and
tautomerization state of the substrate when bound to the active site,
which contains two manganese ions, is not known. Knowledge of the
charge-dependent behavior of arginine in the arginase I environment
would be of utility toward understanding the catalytic mechanism and
designing inhibitors of this enzyme. The arginine<sup>+/0</sup> species,
including all possible neutral tautomers, were modeled using an aminoimidazole
analog as template. All-atom molecular dynamics simulations were then
performed on each of the charged and neutral species. In addition,
a hydroxide ion was included in selected simulations to test its importance.
Results show that the positively charged state of arginine is stable
in the active site of arginase I, with that stabilization facilitated
by the presence of hydroxide. Glu277 is indicated to play a role in
stabilizing arginine in the active site and facilitating its ability
to assume a catalytically competent conformation in the presence of
hydroxide. The reported interactions and modeled arginine-bound arginase
I structures can be used as a tool for structure-based inhibitor design,
as experimental data on the structure of the substrate–enzyme
complex is lacking
A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
Leucine-rich repeat kinase-2 (LRRK2), a cytoplasmic protein containing both GTP binding and kinase activities, has emerged as a highly promising drug target for Parkinson's disease (PD). The majority of PD-linked mutations in LRRK2 dysregulate its GTP binding and kinase activities, which may contribute to neurodegeneration. While most known LRRK2 inhibitors are developed to target the kinase domain, we have recently identified the first LRRK2 GTP binding inhibitor, 68, which not only inhibits LRRK2 GTP binding and kinase activities with high potency in vitro, but also reduces neurodegeneration. However, the in vivo effects of 68 are low due to its limited brain penetration. To address this problem, we reported herein the design and synthesis of a novel analog of 68, FX2149, aimed at increasing the in vivo efficacy. Pharmacological characterization of FX2149 exhibited inhibition of LRRK2 GTP binding activity by ~90% at a concentration of 10 nM using in vitro assays. Furthermore, FX2149 protected against mutant LRRK2-induced neurodegeneration in SH-SY5Y cells at 50-200 nM concentrations. Importantly, FX2149 at 10 mg/kg (i.p.) showed significant brain inhibition efficacy equivalent to that of 68 at 20 mg/kg (i.p.), determined by mouse brain LRRK2 GTP binding and phosphorylation assays. Furthermore, FX2149 at 10 mg/kg (i.p.) attenuated lipopolysaccharide (LPS)-induced microglia activation and LRRK2 upregulation in a mouse neuroinflammation model comparable to 68 at 20 mg/kg (i.p.). Our results highlight a novel GTP binding inhibitor with better brain efficacy, which represents a new lead compound for further understanding PD pathogenesis and therapeutic studies
Recommended from our members
Crystallographic and Computational Insights into Isoform-Selective Dynamics in Nitric Oxide Synthase
In our efforts to develop inhibitors selective for neuronal nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS), we found that nNOS can undergo conformational changes in response to inhibitor binding that does not readily occur in eNOS. One change involves movement of a conserved tyrosine, which hydrogen bonds to one of the heme propionates, but in the presence of an inhibitor, changes conformation, enabling part of the inhibitor to hydrogen bond with the heme propionate. This movement does not occur as readily in eNOS and may account for the reason why these inhibitors bind more tightly to nNOS. A second structural change occurs upon the binding of a second inhibitor molecule to nNOS, displacing the pterin cofactor. Binding of this second site inhibitor requires structural changes at the dimer interface, which also occurs more readily in nNOS than in eNOS. Here, we used a combination of crystallography, mutagenesis, and computational methods to better understand the structural basis for these differences in NOS inhibitor binding. Computational results show that a conserved tyrosine near the primary inhibitor binding site is anchored more tightly in eNOS than in nNOS, allowing for less flexibility of this residue. We also find that the inefficiency of eNOS to bind a second inhibitor molecule is likely due to the tighter dimer interface in eNOS compared with nNOS. This study provides a better understanding of how subtle structural differences in NOS isoforms can result in substantial dynamic differences that can be exploited in the development of isoform-selective inhibitors
- …